Leading-edge AI solution
for 2D mammography enhances
cancer detection performance for clinicians, with improved sensitivity, specificity,
and processing times over previous versions


Latest generation of ProFound AI Risk, now available for digital
breast tomosynthesis, provides an accurate, short-term breast cancer risk
estimation for women, based only on a screening mammogram


iCAD will unveil the latest generation of ProFound
AI® for 2D Mammography this week at the Journées Francophones de Radiologie
(JFR) meeting, which will take place in Paris from Oct. 8-11. The Company will also
showcase its most recent technological advancements at the meeting, including
the latest generations of ProFound AI® for Digital Breast Tomosynthesis (DBT)
and ProFound AI® Risk, in its booth (#226A).  


“The European launch of our third generation of ProFound
AI for 2D Mammography demonstrates iCAD’s steadfast commitment to improving
breast cancer detection for all women worldwide,” said Stacey Stevens,
President of iCAD, Inc. “By using this leading-edge technology, both general
and breast radiologists can potentially improve their accuracy and performance,
which may in turn have a positive impact on women and the healthcare system

The latest generation of ProFound AI for 2D Mammography outperforms
the previous product version, offering standalone performance improvements of
up to 4% increased sensitivity, up to 10% improved specificity and up to 40% faster processing.[1] The advanced deep-learning software
uses advanced neural network image processing and pattern recognition to
analyze mammography images for potential cancers. Suspicious appearing
structures such as densities (masses, architectural distortions, and
asymmetries) and calcification clusters are identified via a contoured line.
Each identified region includes a Certainty of Finding score, which indicates
its match to lesions within the growing ProFound AI enriched database. Each
case also includes a Case Score, which indicates the algorithm’s confidence
level for the case matching malignant cases within the ProFound AI database.
Both scores are designed to assist with clinical decision making; Case Scores
may also be used to prioritize the reading worklist. Designed for seamless
integration in clinical workflow, ProFound AI results can be flexibly
integrated into leading MIS/RIS, and PACS software products. 


“When breast cancer is diagnosed early, survival after
treatment is excellent, over 90% in some countries,[2]” according to Patrick
Toubiana, MD, Radiologist, President and Co-Founder at the C.S.E. Centre
Imagerie Médicale Numérique, Paris, France. “At C.S.E., we have been using
ProFound AI for 2D Mammography and DBT for several years, during which we have
seen iCAD’s constant commitment to improve performance in terms of both
sensitivity and specificity as new versions are released.”


In addition, the new version of ProFound AI Risk will also be available
for demonstration at the iCAD booth at JFR. This solution, now available for
tomosynthesis, provides an accurate estimate of the risk of short-term breast
cancer, which is truly personalized for each woman.


Regular, age-based
mammography screening reduces breast cancer mortality by approximately 20%,[4]
but screening mammography can still miss 20 to 40% of breast cancers.[5],[6]
Many of these cancers are diagnosed as interval breast cancers, defined as
those that emerge after a normal mammogram but before the woman’s next
scheduled screening.


Clinicians have
traditionally considered risk factors such as family history as a way to assess
women’s risks of developing breast cancer, but about 85% of breast cancers
occur in women who have no family history of breast cancer.[7]


“iCAD’s technology offers practical solutions for
physicians and life-saving benefits to women and their families,” said Michele
Debain, Vice President, Europe, Middle East, Africa and APAC at iCAD.

“Additionally, ProFound AI Risk is a unique tool that can
give women a precise indication of their risk of developing breast cancer in one,
two or three years, based on information in their mammogram. This new
information empowers both women and their physicians to actively manage breast
care that is best adapted to the individual and to ultimately discover breast
cancer earlier. Furthermore, ProFound AI Risk provides an additional refinement
of individual risk assessment by taking into account the geographical region of
a woman and her country’s incidence and mortality rates. This is a first-of-its-kind
solution that keeps focusing on personalized, individually tailored breast care.”


“We are proud to be the first private medical imaging
center in France to benefit from iCAD’s latest solution, ProFound AI Risk,” Dr.
Toubiana added. “This innovative technology calculates the individual risk of
breast cancer, from the analysis of information contained in the mammogram,
such as density, texture, asymmetries and patient age, which is a much more
precise approach than other risk models currently offered. This new algorithm
allows us to identify women who are at higher risk of developing short-term
breast cancer, and to personalize our follow-up for these women.”


iCAD will sponsor a lunch symposium at JFR featuring Dr. Toubiana
and Julia Arfi Rouche, MD, Institut Gustave Roussy in Villejuif, France, on
Sunday, Oct. 10 at 1:00 pm in room 342A. Drs. Toubiana and Rouche will review
published clinical studies demonstrating the effectiveness of ProFound AI®
solutions for breast cancer detection and risk, and showcase clinical cases from
private and public imaging centers. 


[1] iCAD data on file. Standalone
performance compared to iCad’s previous generation of CAD. Performance varies
by vendor.

[2] World Health Organization. Breast
Cancer Fact Sheet. Accessed via https://www.who.int/news-room/fact-sheets/detail/breast-cancer#:~:text=Partial%20treatment%20is%20less%20likely%20to%20lead%20to%20a%20positive%20outcome.&text=Survival%20of%20breast%20cancer%20for,and%2040%25%20in%20South%20Africa.

[3] Eriksson M, Czene K, Strand F,
Zackrisson S, Lindholm P, Lång K, Förnvik D, Sartor H, Mavaddat N, Easton D,
Hall P. Identification of Women at High Risk of Breast Cancer Who Need
Supplemental Screening. Radiology. 2020 Nov;297(2):327-333. doi:
10.1148/radiol.2020201620. Epub 2020 Sep 8. PMID: 32897160.

[4] Marmot M, Altman G, Cameron A, et
al.  The benefits and harms of breast
cancer screening: an independent review. 
Br J Cancer. 2013;108(11):2205-2240.

[5] NIH National Cancer Institute.
Mammograms Fact Sheet. Accessed via https://www.cancer.gov/types/breast/mammograms-fact-sheet.

[6] Lauby-Secretan B, Scoccianti C,
Loomis D et al.; Breast-cancer screening–viewpoint of the IARC Working Group;
N Engl J Med. 2015 Jun 11;372(24):2353-8. doi: 10.1056/NEJMsr1504363.

[7] U.S. Breast Cancer Statistics.
Breastcancer.org. Accessed via